ALE1
Hypophosphatasia (HPP)
Pre-clinicalActive
Key Facts
About Alesta Therapeutics
Alesta Therapeutics is an emerging private biotech company developing oral small molecule drugs for rare diseases, with its lead program, ALE1, targeting Hypophosphatasia (HPP). The company is backed by a €65 million Series A financing round from leading life science investors, announced in January 2025. With a globally experienced team, Alesta emphasizes a patient-centric development model, combining scientific precision with practical advantages like oral delivery and cost-effectiveness. The company is preparing to highlight clinical progress for ALE1 at a major industry conference in early 2026.
View full company profile